Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sanofi Delivers First Medicines from Global Health Unit’s Impact Brand Portfolio
Details : Lovenox (enoxaparin sodium) is a novel small molecule Antithrombin-III activator. It is an anticoagulant medicine indicated for the treatment of venous thromboembolism including deep vein thrombosis.
Product Name : Lovenox
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 19, 2023
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Agreement
Sanofi and Minapharm Sign an Exclusive Agreement for Localizing the Manufacture of Clexane®
Details : The agreement aims for the for the localization of the full range of its flagship market leader product, Clexane (enoxaparin sodium), used to prevent clots from getting bigger or stopping new clots from forming.
Product Name : Clexane
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 12, 2023
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lovenox-Generic (enoxaparin sodium) is a Factor XI/XIa inhibitor with a Prefilled Syringes with 30mg, 40mg, 60mg, 80mg, 100mg, 120mg, and 150mg strengths low molecular weight heparin (LMWH), is an anticoagulant that helps to prevent thrombosis.
Product Name : Lovenox-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 06, 2023
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Enoxaparin sodium binds to antithrombin III, a serine protease inhibitor, forming a complex that irreversibly inactivates factor Xa, which is frequently used to monitor anticoagulation in the clinical setting.
Product Name : Lovenox-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 20, 2023
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Desjardins Capital Markets
Deal Size : $10.0 million
Deal Type : Private Placement
Details :
Product Name : Redesca
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 24, 2021
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Desjardins Capital Markets
Deal Size : $10.0 million
Deal Type : Private Placement
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Group Purchasing Organizations
Deal Size : Undisclosed
Deal Type : Agreement
Details :
Product Name : Redesca
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 13, 2021
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Group Purchasing Organizations
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Hematology
Study Phase : Undisclosed
Sponsor : Premier
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Researchers found that patients on a prophylactic dose of the anticoagulants enoxaparin or heparin have shorter hospital stays, lower cost, and better clinical outcomes in Covid-19 patient.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 15, 2021
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Sponsor : Premier
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Valeo Pharma’s Redesca™ Receives Positive Recommendation for Public Reimbursement in Quebec
Details :
Product Name : Redesca
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 25, 2021
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Meitheal Pharmaceuticals Announces Launch of Enoxaparin Sodium Injection, USP in the United States
Details : Meitheal Pharmaceuticals has launched Enoxaparin Sodium Injection, generic equivalent of Lovenox®, in the United States market. Meitheal licenses Enoxaparin Sodium Injection exclusively through its partnership with Nanjing King-Friend Biochemical Pharma...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 28, 2020
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable